Redx Pharma Lung Disease Treatment Receives US FDA Orphan Drug Designation
Provided by
Dow Jones
By Michael Susin
Redx Pharma's lung disease treatment RCX007 has received orphan drug designation from the U.S. Food and Drug Administration for the potential treatment of idiopathic pulmonary fibrosis, the company said Monday.
The clinical-stage biotechnology company said the designation provides various development and commercial incentives, including market exclusivity, in order to address unmet demand.
The treatment is currently in a Phase 2 clinical study for IPF, with topline data expected to be released in the first quarter of 2024.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
August 21, 2023 03:02 ET (07:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains